<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272021</url>
  </required_header>
  <id_info>
    <org_study_id>504</org_study_id>
    <nct_id>NCT04272021</nct_id>
  </id_info>
  <brief_title>Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children</brief_title>
  <acronym>MIMOSA</acronym>
  <official_title>Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Eugenio Medea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Eugenio Medea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MIMOSA study aims to characterize from behavioral, neurophysiological and neurocognitive
      perspectives children and adolescents with attention deficit hyperactivity disorder (ADHD),
      in order to identify a possible biomarker of response to medication treatments. To achieve
      this aim, in the study children with ADHD (drug naive) are recruited and undergo behavioral
      and clinical screenings, neurocognitive profile, and neurophysiological evaluation with
      functional near infrared spectroscopy (fNIRS). ADHD group is evaluated before the beginning
      of medications, at first dose of medication (only imaging evaluation fNIRS), and after a
      period of two/three months of continuous treatment with medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD rating scale</measure>
    <time_frame>2-3 months</time_frame>
    <description>Clinical improvement measured with ADHD rating scale, percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>2-3 months</time_frame>
    <description>Clinical improvement measured with CGI-s (Clinical Global Impression - severity)(minimum value: 1 = &quot;normal, not ill&quot;; maximun value: 7 = &quot;very severely ill&quot; )</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in functional neuroimaging</measure>
    <time_frame>2-3 months</time_frame>
    <description>functional Near Infrared Spectroscopy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>ADHD sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children with a diagnosis of ADHD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>standard therapy for ADHD</description>
    <arm_group_label>ADHD sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of ADHD according to DSM-5 (Diagnostic and Statistical Manual of Mental
             Disorders-5) criteria;

          -  drug naive

        Exclusion Criteria:

          -  presence of intellectual disability, neurological diseases, epilepsy, genetic
             syndromes

          -  and previous treatment with psychoactive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Nobile, MD, PhD</last_name>
    <phone>+39 031877813</phone>
    <email>maria.nobile@lanostrafamiglia.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Eugenio Medea</name>
      <address>
        <city>Bosisio Parini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Nobile, MD, PhD</last_name>
      <phone>+39031877813</phone>
      <email>maria.nobile@lanostrafamiglia.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

